Jung-Hoon Hoon Kim

Dr. Jung-Hoon Hoon Kim

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2011 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
JYJ. H. Yi
J. H. Yi
JKJung-Hoon Hoon Kim
Jung-Hoon Hoon Kim
KBK. K. Baek
K. K. Baek
TLT. Lim
T. Lim
DLD. J. Lee
D. J. Lee
WKWon Seog Kim
Won Seog Kim
Background: The incidence and risk factors of central nervous system (CNS) involvement in peripheral T-cell lymphomas (PTCLs) are still unclear. Patients and methods: We analyzed 228 patients with PTCLs, excluding cases of extranodal natural killer/T-cell lymphoma and primary cutaneous T-cell lymphoma, by retrospectively collecting the clinical features and outcomes of the patients. Results: Twenty events (8.77%, 20/228) of CNS involvement were observed during a median follow-up period of 13.9 months (range 0.03–159.43). Based on univariate analysis, elevated serum lactate dehydrogenase (LDH) level [P = 0.019, relative risk (RR) 5.904, 95% confidence interval (CI) 1.334–26.123] and involvement of the paranasal sinus (P = 0.032, RR 3.137, 95% CI 1.105–8.908) adversely affect CNS involvement. In multivariate analysis, both were independently poor prognostic factors for CNS relapse [elevated LDH level: P = 0.011, hazard ratio (HR) 6.716, 95% CI 1.548–29.131; involvement of the paranasal sinus: P = 0.008, HR 3.784, 95% CI 1.420–10.083]. The survival duration of patients with CNS involvement was significantly shorter than that of the patients without CNS involvement (P = 0.009), with median overall survival of 7.60 months (95% CI of 4.92–10.28) versus 27.43 months (95% CI of 0.00–57.38), respectively. Conclusions: Elevated LDH level and involvement of the paranasal sinus are two risk factors for CNS involvement in patients with PTCLs. Considering the poor prognoses after CNS relapse, prophylaxis should be considered with the presence of any risk factor.

1 July 2019 in Journal of Pain and Symptom Management
Verified
Journal Article
Closed access
YWYoung-Woong Won
Young-Woong Won
HCHye Sook Chun
Hye Sook Chun
MSMinjeong Seo
Minjeong Seo
RKRock Bum Kim
Rock Bum Kim
JKJung-Hoon Hoon Kim
Jung-Hoon Hoon Kim
JKJung Hun Kang
Jung Hun Kang

1 November 2021 in European Journal of Cancer
Verified
Journal Article
Closed access
SGSe-Il Go
Se-Il Go
SLSang-Cheol Lee
Sang-Cheol Lee
WBWoo Kyun Bae
Woo Kyun Bae
DZDae Young Zang
Dae Young Zang
HLHyun Woo Lee
Hyun Woo Lee
JKJung Hun Kang
Jung Hun Kang

4 June 2018 in Cancer Communications
Verified
Journal Article
Open access
PDF file
JKJung-Hoon Hoon Kim
Jung-Hoon Hoon Kim
SLSang‐Cheol Lee
Sang‐Cheol Lee
SOSung Yong Oh
Sung Yong Oh
SSSeo‐Young Song
Seo‐Young Song
NLNamsu Lee
Namsu Lee
JKJung Hun Kang
Jung Hun Kang
Background: Combination therapy with oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) chemotherapy drastically improves survival of advanced pancreatic cancer patients. However, the efficacy of FOLFIRINOX as a second‐line treatment after gemcitabine failure has not been tested prospectively. We investigated the feasibility and safety of attenuated FOLFIRINOX in patients with gemcitabine‐refractory advanced pancreatic cancer. Methods: A multicenter phase II prospective open‐label, single‐arm study was conducted at 14 hospitals. Patients with histologically proven invasive ductal pancreatic adenocarcinoma, a measurable or evaluable lesion, Eastern Cooperative Oncology Group performance status 0 or 1, adequate organ function, and aged 19 years or older were eligible. Attenuated FOLFIRINOX consisted of oxaliplatin 65 mg/m 2 , irinotecan 135 mg/m 2 , and leucovorin 400 mg/m 2 injected intravenously on day 1 and 5‐fluorouracil 2000 mg/m 2 continuously infused intravenously over 46 h on days 1–2, repeated every 2 weeks. The primary endpoint was progression‐free survival from the initiation of FOLFIRINOX. Secondary endpoints were the objective response rate, disease control rate, overall survival, safety, and tolerability. We estimated overall survival and progression‐free survival using the Kaplan–Meier methods. Results: We enrolled 39 patients from 14 institutions. The objective response rate was 10.3%, while the disease control rate was 64.1%. The 6‐month and 1‐year overall survival rates were 59.0% and 15.4%, respectively. Median progression‐free survival and overall survival were 3.8 months (95% confidence interval [CI] 1.5–6.0 months) and 8.5 months (95% CI 5.6–11.4 months), respectively. Grade 3 or 4 adverse events were neutropenia (41.0%), nausea (10.3%), anorexia (10.3%), anemia (7.7%), mucositis (7.7%), pneumonia/pleural effusion (5.1%), and fatigue (5.1%). One treatment‐related death attributable to septic shock occurred. Conclusion: Attenuated FOLFIRINOX may be promising as a second‐line therapy for gemcitabine‐refractory pancreatic cancer.

1 January 2019 in Journal of Cancer
Verified
Journal Article
Open access
SYSang Eun Yoon
Sang Eun Yoon
JKJung-Hoon Hoon Kim
Jung-Hoon Hoon Kim
SLSu Jin Lee
Su Jin Lee
JLJeeyun Lee
Jeeyun Lee
SPSe Hoon Park
Se Hoon Park
SKSeung Tae Kim
Seung Tae Kim
Background: Gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC) is a heterogeneous disease in terms of embryonic origin, aggressiveness, prognosis, and genomic profiling. Data regarding the efficacy of etoposide and cisplatin (EP) as a standard treatment of the primary tumor site in GEP-NEC are limited.

1 January 2016 in Journal of Cancer
Verified
Journal Article
Open access
JKJung-Hoon Hoon Kim
Jung-Hoon Hoon Kim
BKBum Jun Kim
Bum Jun Kim
HKHyeong Su Kim
Hyeong Su Kim
Cancer immunotherapy is at dawn of the Renaissance after the Medieval Dark Ages. Recent advances of understanding tumor immunology and molecular drug development are leading us to the epoch of cancer immunotherapy. Some types of immunotherapy have shown to provide survival benefit for patients with solid tumors such as malignant melanoma, renal cell carcinoma, or non-small cell lung cancer. Several studies have suggested that immune checkpoint inhibition might be effective in some patients with gastrointestinal cancers. However, the era of cancer immunotherapy in gastrointestinal cancers is still in an inchoate stage. Here we briefly review the current status and perspective of immunotherapeutic approaches in patients with gastrointestinal cancers.